Regulus Therapeutics, a biopharmaceutical company focusing on microRNA-targeted therapies, is gaining investor attention due to promising clinical trial results. Its innovations could revolutionize treatments for diseases like cancer. As positive outcomes continue, Regulus may achieve regulatory approvals and boost its NASDAQ stock price, positioning itself as a leader in biotech.